We examined effect of the tyrosine kinase inhibitor herbimycin A on A431 human epidermoid carcinoma cells which over-express epidermal growth factor (EGF) receptor. Herbimycin A inhibited the autophosphorylation of EGF-stimulated receptors in intact cells both time-and dose-dependently. The inhibition was found to be due to a decrease in the level of expression of the receptor amount, because herbimycin A equally decreased the receptor quantity and EGF-stimulated receptor kinase activity in intact cells, but did not exhibit a direct inhibitory effect on EGF receptor kinase activity In, vitro. The decrease of the level of EGF receptor was also confirmed by 125I-EGF binding to herbimycin INTRODUCTION
INTRODUCTION
It is known that receptor-type tyrosine kinases are deeply involved in signalling pathways for cell proliferation. Epidermal growth factor (EGF) receptor is a typical receptor-type tyrosine kinase (reviewed by Carpenter [1] ); the primary structure of its cytoplasmic domain is homologous to that of the product of verbB, the transforming gene of avian erythroblastosis virus, and is thought to be the c-erbB proto-oncogene product. Many human tumour cells of ectodermal origin (glioblastoma, squamous carcinoma of lung, mammary gland, oesophagus and skin) are known to express extraordinarily high numbers of EGF receptors, suggesting a primary role of the receptor in the development of these neoplasias. Human epidermoid cells are good materials with which to investigate a possible causal relationship between the excess expression of EGF receptor and malignant cell growth.
Herbimycin A was found to reverse the transformation by src oncogene by inactivating the kinase activity of p60-src [2] . It also reversed the transformation of other tyrosine kinase-encoding oncogenes (yes, fps, erb-B, abl, ros), but did not reverse those of raf, ras or myc, suggesting that herbimycin A is a specific inhibitor of tyrosine kinases [3] . Herbimycin A has recently been demonstrated to inhibit tyrosine kinases specifically in vitro without affecting protein kinase A or protein kinase C [4] . The inhibition of the kinase activity appeared to be due to its binding to cysteine residue(s) of tyrosine kinase, like thiol reagent, and its direct binding has recently been confirmed by labelling v-Src and BCR-ABL tyrosine kinases with [14C]herbimycin A [5] .
Although we have studied extensively the effect of herbimycin A on tyrosine kinases which belong to the non-receptor class, we have not determined its effect on the other type of tyrosine A-treated cells, and Scatchard analysis showed that the decrease in the receptor number occurred in the major population of the low-affinity binding ones, whereas the number with high-affinity binding was unaffected. Interestingly, although the proliferation of A431 cells was inhibited by EGF, herbimycin A converted EGF into a stimulatory ligand for cell growth, as determined by both cell number and DNA synthesis. These findings indicated that herbimycin A decreased the level of expression of EGF receptor by a mechanism other than inactivation of the receptor kinase and reversed the transformed phenotype of A431 cells to a normal one in the proliferative response to EGF.
kinases, which belong to the receptor class. We therefore investigated the effect of herbimycin A on A431 human epidermoid carcinoma cells that over-express EGF-receptor tyrosine kinase and found that it markedly decreased the autophosphorylation of EGF receptors in intact cells. Unexpectedly, however, it was found that the decrease in the receptor phosphorylation was due to the decrease in amount of receptor rather than to inactivation of kinase activity. Interestingly, herbimycin A converted EGF into a stimulatory ligand to proliferate A431 cells.
MATERIALS AND METHODS Materials
Herbimycin A was isolated as described previously [6] and was used from a 1.0 mg/ml stock solution dissolved in dimethyl sulphoxide (DMSO). Erbstatin was provided by Dr. T. Takeuchi, Institute of Microbial Chemistry (Tokyo, Japan). Tyrphostin (3,4,5-trihydroxybenzylidene malononitrile) was purchased from GIBCO BRL (Gaithersburg, MD, U.S.A. 
Immunoprecipitatlon
Labelled cells were washed with PBS and solubilized with RIPA buffer (20 mM Tris/HCl, pH 7.2, 0.15 M NaCl, 1 % Triton X-100, 1% sodium deoxycholate, 0.1 % SDS, 2 mM EDTA, 100 kallikrein-inactivator units/ml aprotinin, 100 ,uM Na3VO4, 1 mM phenylmethanesulphonyl fluoride, and 20 ,ug/ml each of antipain, pepstatin and leupeptin), or for [35S]methionine-labelled cells in accordance with the conditions for the kinase reaction, with HNTG buffer (20 mM Hepes, pH 7.5, 150 mM NaCl, 1 % Triton X-100, 10% glycerol, 1 mM EDTA, 100 kallikreininactivator units/ml aprotinin, 100 1sM Na3VO4, 1 mM phenylmethanesulphonyl fluoride, and 20 ,ug/ml each of antipain, pepstatin and leupeptin) on ice for 30 min. Lysates were transferred to Eppendorf tubes, and centrifuged to remove debris. The supernatants, containing a fixed amount of protein, were incubated with anti-(EGF receptor) antibody for 1 h at 0°C, followed by treatment with the second antibody. Next, immune complexes were collected with formaldehyde-fixed Protein A (Pansorbin; Calbiochem, San Diego, CA, U.S.A.) and washed with RIPA buffer. The immunoprecipitates were suspended in 30 ,ul of electrophoresis sample buffer (42 mM Tris/HCl, pH 6.8, 10% glycerol, 2.3 % SDS, 5% 2-mercaptoethanol, 0.002% Bromophenol Blue), boiled for 3 min, and spun down. The supernatants were analysed by SDS/PAGE in 7.5 % gels.
To estimate phosphorylation of the receptor, the 32P radioAlternatively, radioactivities in Figure 2 and Table 1 were analysed by using a Fujix BAS2000 bio-image analyser. For kinase assay examining the direct effect of inhibitors, the assay was conducted as described above, except that 2 ,1 of 10-fold-concentrated inhibitor dissolved in 10% DMSO was included throughout the incubation.
151-EGF-binding assay
'211-EGF. binding to A431 cells was performed principally by the method of Carpenter [7] , but at 4°C, for 2 h. Cells seeded in 24-well plates (1.5 x 105 cells per 2 cm2 well) were incubated in DME containing 10 % FCS for 1 day and were treated with or without herbimycin A for 20 h. After removing the medium, the cells were washed with DME (without serum), and placed in 0.25 ml of binding medium (20 mM Hepes, pH 7.4, and 1 % BSA in DME). 1251-EGF (diluted with unlabelled EGF) was added and the cells were incubated on ice for 4 h. Non-specific binding was measured by adding a 100-fold excess of unlabelled EGF. After removing the medium, cells were washed with PBS and solubilized with 0.5 ml of 0.1 M NaOH. The amount of radioactivity was determined in a y-radiation scintillation counter (Packard MINAXIy). Assays were carried out in duplicate.
RESULTS

Effect of herbimycin A on EGF-stimulated EGF-receptor kinase activity
We first examined the ability of herbimycin A to inhibit EGFstimulated EGF-receptor autophosphorylation in intact cells. A43 1 cells were treated with herbimycin A for 4 or 24 h and were labelled with [32P]Pi for the last 4 h in the absence or presence of EGF (50 ng/ml). Figure 1 shows that EGF stimulated the EGFreceptor autophosphorylation. Treatment of cells with up to 10 ,ug/ml herbimycin A for 4 h had no effect on EGF-receptor phosphorylation, but significant inhibition of phosphorylation was found after 24 h of treatment ( Figure 1, lanes f-h) . With 24 h treatment, phosphorylation of the EGF receptor was inhibited in a dose-dependent manner, and with 1.0 ,ug/ml herbimycin A the level of EGF-receptor phosphorylation was about 26 % of the control. kinase activity by 6 [2, 8] . As shown in Figure 3( (Figure 3a) . These results suggested that the decrease in the receptor kinase activity was due to the decrease in receptor amount, rather than to inhibition of the specific activity of the receptor kinase. We next examined the direct effect of herbimycin A on EGFreceptor kinase activity, using cell lysates from A431 cells in a protein kinase assay. We found that, under the conditions used, herbimycin A at 1-100 ,ug/ml was unable to inhibit EGF receptor kinase activity (Table 1) . For comparison, the kinase assay was performed in the presence of either erbstatin or tyrphostin, wellcharacterized inhibitors of EGF-receptor kinase activity [9] [10] [11] .
In contrast with herbimycin A, these inhibitors significantly inhibited the receptor kinase activity (Table 1) . In a separate experiment, we also examined the direct effect of herbimycin A, using an A431-cell membrane fraction, but no inhibitory effect was observed (results not shown).
Effect of herbimycin A on EGF-receptor expression on the cell surface as determined by 1251-EGF binding
To examine the effect of herbimycin A on expression of the EGF receptor on the cell surface, we next determined the number of binding sites for EGF. The binding assay was performed with 125I-labelled EGF after A431 cells were treated with 1.0 ag/ml herbimycin A for 20 h. In agreement with the previous reports [12] [13] [14] , a Scatchard-plot profile showed the existence of two affinity classes of EGF receptors (Figure 4) . The dissociation constants were estimated to be Kdl = 2.4 x 10-8 M and Kd2 = 6 x 10-10 M, and the receptor numbers to be 1.0 x 106 and 0.72 x 105 per cell, for low-and high-affinity receptors respectively. The analysis for herbimycin A-treated cells still indicated the existence of two affinity classes (Kd values 7.7 x 10-9 M and 1.1 x 10-9 M). However, the number of low-affinity receptors was significantly decreased to about 30-40 % of the control, whereas that for high-affinity binding receptors was unchanged. Thus the 125I-EGF-binding capacity of herbimycin A-treated cells correlated well with the decreased level of the receptors as quantified by immunoprecipitation. The decreased EGF-binding capacity was not due to a direct inhibition of EGF binding to the cells, because herbimycin A even at 1O ug/ml had no effect on the binding of 125I-EGF to the cells (results not shown). Effect of herbimycin A on EGF-mediated growth of A431 cells
We next examined the effect of herbimycin A on cell growth, because the A431 cell line is unusual in that its growth is inhibited by EGF, and the growth-inhibitory effect of EGF has been postulated to be due to the expression of an extremely large number of EGF receptors [15] . We undertook this experiment using two different cell densities, since the level of EGF-receptor expression on the cell surface was reported to be altered according to cell density [16] . As shown in Figure 5 , A431-cell growth was inhibited by EGF in a dose-dependent manner, and this was more obvious at a lower cell density, whereas additions of herbimycin A at 0.1-0.3 ,ug/ml blocked the inhibition of cell growth (Figure 5a ). At a higher cell density, the addition of herbimycin A actually caused a stimulation ofcell growth ( Figure  Sb) . The conversion of EGF into a stimulatory ligand for A431-cell growth was also observed in an assay determining DNA synthesis monitored by [3H]thymidine incorporation. Figure 6 shows the DNA synthesis in A431 cells exposed to herbimycin A in the absence or presence of several concentrations of EGF. The ordinate of the Figure shows that low concentrations of EGF (1-10 ng/ml) stimulated DNA synthesis, whereas a high concentration of EGF (100 ng/ml) inhibited the synthesis, roughly agreeing with the data shown in Figure 5 (b). Increasing concentrations of herbimycin A inhibited DNA synthesis in the absence or presence of 1 ng/ml EGF. However, when herbimycin A was added along with 10 or 100 ng/ml EGF, DNA synthesis was stimulated. As shown in Figure 6( [5, 24] , and these residues are also present in the kinase domain of the EGF receptor [25] [26] .
It is well known that A431-cell growth is inhibited by high concentrations of EGF [15] . Interestingly, however, we found in the present study that herbimycin A converted EGF into a stimulatory ligand for A431-cell growth. Kawamoto et al. [27] previously investigated the relationship between the concentration of EGF receptor and effects of the EGF on cell proliferation, using variant A431 cells. They found that several clonal variants that required EGF-mediated growth inhibition expressed 2-4-fold more EGF receptor than did their respective parental variant. Thus it appears that the decreased concentration of EGF receptor that was induced by herbimycin A altered the proliferative response to EGF. The stimulatory effect of herbimycin A in the proliferative response of A431 cells to EGF was demonstrated with both high and low cell densities; since a more obvious effect was obtained at the higher cell density (Figure Sb) , DNA synthesis was examined under this condition, and significant stimulation was observed. The EGF-binding assay was conducted at this high cell density, and some light was shed on cell growth stimulation; this is discussed below.
Characterization of the cell-surface EGF receptor by 125I-EGF binding showed that the decrease in the receptor number occurred in the major population with low-affinity binding, whereas the number with high-affinity binding was unaffected. The effects of monoclonal anti-(EGF receptor) antibodies on cell growth and EGF-receptor activity of the following are interesting. Gregoriou and Rees [28] reported that a monoclonal antibody showed a specific inhibition of low-affinity receptor of A431 cells, and growth of A431 cells treated with this antibody was stimulated at high concentrations of EGF. Behzadian and Shimizu [14] reported a similar result, in that an antibody that interacted preferentially with low-affinity binding blocked 70 % of the EGF binding, but did not inhibit EGF-stimulated DNA synthesis in normal human fibroblasts (HFK). Thus the present data, together with these observations, strongly suggest that high-affinity binding of the receptor mediates the stimulation of DNA synthesis by EGF, and that over-expression of low-affinity EGF receptor plays a role in cell-growth inhibition by EGF, although the molecular state and precise roles of these two classes in relation to signal transduction remain unknown. Herbimycin A may therefore become a useful biochemical reagent to elucidate these points.
Some cancer cells, especially squamous-cell carcinoma of oesophagus, lung and skin, are known to express extremely high levels of EGF receptor [29, 30] . There is a correlation between EGF-receptor levels and the malignancy [31] : the growth of such cell lines when planted in vivo was stimulated by the administration of EGF to mice [32] . These results suggested that amplification of the EGF receptor is attributable to progression of the tumour. Therefore, inhibitors such as herbimycin A that lower EGF-receptor concentration may be beneficial in treatment of these types of cancers.
